Detalhe da pesquisa
1.
Protective Effects of a synthetic glycosaminoglycan mimetic (OTR4132) in a rat immunotoxic lesion model of septohippocampal cholinergic degeneration.
Glycoconj J
; 39(1): 107-130, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35254602
2.
Immunothrombotic dysregulation in chagas disease and COVID-19: a comparative study of anticoagulation.
Mol Cell Biochem
; 476(10): 3815-3825, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34110554
3.
RGTA® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients.
Glycoconj J
; 34(3): 325-338, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27924424
4.
Refractory sickle cell leg ulcer: is heparan sulphate a new hope?
Int Wound J
; 13(1): 35-8, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24618185
5.
A Retrospective Self-Controlled Study Evaluating the Prophylactic Effects of CACIPLIQ20 on Postsurgical Scars.
Aesthet Surg J Open Forum
; 5: ojad031, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37051418
6.
Regenerating matrix-based therapy for chronic wound healing: a prospective within-subject pilot study.
Int Wound J
; 8(1): 85-95, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21078132
7.
ReGeneraTing Agents (rgta®) technology combined with antibiotics improves outcomes for infections in the upper limb.
Clin Case Rep
; 9(3): 1083-1091, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33768787
8.
Stimulated neovascularization, inflammation resolution and collagen maturation in healing rat cutaneous wounds by a heparan sulfate glycosaminoglycan mimetic, OTR4120.
Wound Repair Regen
; 17(6): 840-52, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19903305
9.
ReGeneraTing Agents (RGTA®): A new option for healing and improving treatment outcomes for traumatic and burn injuries of the hand.
Clin Case Rep
; 7(4): 619-625, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30997049
10.
Case Reports for Topical Treatment of Corneal Ulcers with a New Matrix Therapy Agent or RGTA® in Dogs.
Vet Sci
; 6(4)2019 Dec 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31847217
11.
Matrix therapy is a cost-effective solution to reduce amputation risk and improve quality of life: pilot and case studies.
Regen Med Res
; 7: 2, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31821145
12.
Heparan Sulfate Mimetics Accelerate Postinjury Skeletal Muscle Regeneration.
Tissue Eng Part A
; 25(23-24): 1667-1676, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31062647
13.
Heparan Sulfate Mimetics: A New Way to Optimize Therapeutic Effects of Hydrogel-Embedded Mesenchymal Stromal Cells in Colonic Radiation-Induced Damage.
Sci Rep
; 9(1): 164, 2019 01 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-30655576
14.
RGTA OTR 4120, a heparan sulfate proteoglycan mimetic, increases wound breaking strength and vasodilatory capability in healing rat full-thickness excisional wounds.
Wound Repair Regen
; 16(2): 294-9, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18318813
15.
Significant reduction in neural adhesions after administration of the regenerating agent OTR4120, a synthetic glycosaminoglycan mimetic, after peripheral nerve injury in rats.
J Neurosurg
; 109(5): 967-73, 2008 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-18976093
16.
ReGeneraTing Agents (RGTA®) are a new option to improve amputation outcomes in the recovery of severe hand injuries.
Clin Case Rep
; 6(11): 2061-2069, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30455892
17.
Evaluation of a new matrix regenerating agent in patients with Sjögren syndrome and superficial ulcerative keratitis resistant to conventional therapy: A report of 3 cases.
Medicine (Baltimore)
; 97(10): e9935, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29517701
18.
A heparan sulfate-based matrix therapy reduces brain damage and enhances functional recovery following stroke.
Theranostics
; 8(21): 5814-5827, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30613264
19.
Periodontal reconstruction by heparan sulfate mimetic-based matrix therapy in Porphyromonas gingivalis-infected mice.
Heliyon
; 4(8): e00719, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30101201
20.
Randomized controlled trial demonstrates the benefit of RGTA® based matrix therapy to treat tendinopathies in racing horses.
PLoS One
; 13(3): e0191796, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29522564